Bioretec Receives CMS Pass-Through Payment for the US Market →
logo
logo
  • Home
  • Products
  • Company
  • News
  • Contact
  • Activa
  • RemeOs™
  • Investors
  1. Home
  2. Press Release
  3. Bioretec Ltd – Managers’ transactions – Frank Sarcone
November 16, 2026

Bioretec Ltd – Managers’ transactions – Frank Sarcone

Bioretec Ltd – Managers’ transactions – Frank Sarcone

Bioretec Ltd | Company release | 16 November 2026 at 4:15 p.m. EET

Bioretec Oy – Managers’ Transactions

____________________________________________

Person subject to the notification requirement

Name: Frank Sarcone

Position: Other senior manager

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 180727/8/6

____________________________________________

Transaction date: 2026-11-16

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Oy, optio-ohjelma 2026A

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 15247567 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 15247567 Volume weighted average price: 0 EUR

For additional information

Sarah van Hellenberg Hubar-Fisher
CEO
+31 6 1544 8736
sarah.hubar-fisher@bioretec.com

Panu Mikkonen
CFO
+358 50 4833 707
panu.mikkonen@bioretec.com

Certified Adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with bioabsorbable implant technologies. The company offers two product families, Activa and RemeOs™, both based on advanced bioabsorbable materials. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec’s Activa product family features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications.

The company’s latest innovation, the RemeOs™ product family, is based on a high-performance magnesium alloy and hybrid composite. The first RemeOs™ product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. To date, the RemeOs™ product line has received three FDA Breakthrough Device Designations.

To learn more about Bioretec, visit www.bioretec.com

Share this article

  • Prev
  • Next
Better healing –  better life

Products

Product overviewActivaRemeOs

About Bioretec

CompanyCareersNews & EventsStoriesSales & Marketing Hub

Financials

InvestorsTerms and Conditions of Sale

Connect

ContactDistributors

Newsletter

 
 

Sign up to receive updates on Bioretec’s webinars, events, publications, and products. By subscribing, you agree to our privacy policy.

© Bioretec. All rights reserved. Specifications are subject to change without notice.

Privacy Policy
Cookies